Inflammatory bowel disease (IBD) is a chronic nonspecific gastrointestinal inflammatory disease, which includes Ulcerative colitis (UC) and Crohn's disease (CD). The etiology of IBD is multifactorial and closely associated with genetic susceptibility, the immune system, environmental factors, and microbiome. Irritable bowel syndrome (IBS) is a functional bowel disease. The etiology of IBS is also multifactorial, including intestinal mucosal barrier disruption, intestinal low-grade inflammation, intestinal flora imbalance, intestinal motility dysfunction, gut-brain axis dysfunction, visceral hypersensitivity, and psychological disorders. Recently, gut microbiota has been widely acknowledged to play an important role in the occurrence and development of IBD and IBS. Manipulation of gut microbiota through dietary interventions, probiotics, prebiotics, synbiotics, antibiotics, fecal microbiota transplantation (FMT), and other methods represents a promising therapeutic measure in patients with IBD and IBS. However, mechanisms of interaction between gut microbiota and IBD or IBS remain not fully understood. Besides, the therapeutic role of gut microbiota metabolites and specific strains in IBD and IBS also needs to be further explored.
This Research Topic aims at discussing the efficacy and safety of manipulation of gut microbiota through dietary interventions, probiotics, prebiotics, synbiotics, antibiotics, fecal microbiota transplantation (FMT), and other methods in the management and treatment of IBD and IBS. And we would also like to update recent advances and evidence in novel gut microbiota manipulation tools in the management and treatment of IBD and IBS. We would like to explore the exact relationship between specific gut bacteria and IBD subtypes (Ulcerative colitis and Crohn’s disease) or IBS subtypes (IBS-C, IBS-D, IBS-M), and elucidate the mechanisms underlying the role of gut microbiota or metabolites in IBD and IBS through gut immunity, gut inflammation, gut microenvironment, and gene and protein regulation.
We welcome submissions of Original Research, Reviews, and Commentaries. We would like contributors to address the following topics:
1. The efficacy and safety of manipulation of gut microbiota through dietary interventions, probiotics, prebiotics, synbiotics, antibiotics, fecal microbiota transplantation (FMT), and other methods in the management and treatment of IBD and IBS.
2. The exact relationship between specific gut bacteria and IBD subtypes (Ulcerative colitis and Crohn’s disease) or IBS subtypes (IBS-C, IBS-D, IBS-M).
3. The mechanisms underlying the role of gut microbiota or its metabolites in IBD and IBS.
Inflammatory bowel disease (IBD) is a chronic nonspecific gastrointestinal inflammatory disease, which includes Ulcerative colitis (UC) and Crohn's disease (CD). The etiology of IBD is multifactorial and closely associated with genetic susceptibility, the immune system, environmental factors, and microbiome. Irritable bowel syndrome (IBS) is a functional bowel disease. The etiology of IBS is also multifactorial, including intestinal mucosal barrier disruption, intestinal low-grade inflammation, intestinal flora imbalance, intestinal motility dysfunction, gut-brain axis dysfunction, visceral hypersensitivity, and psychological disorders. Recently, gut microbiota has been widely acknowledged to play an important role in the occurrence and development of IBD and IBS. Manipulation of gut microbiota through dietary interventions, probiotics, prebiotics, synbiotics, antibiotics, fecal microbiota transplantation (FMT), and other methods represents a promising therapeutic measure in patients with IBD and IBS. However, mechanisms of interaction between gut microbiota and IBD or IBS remain not fully understood. Besides, the therapeutic role of gut microbiota metabolites and specific strains in IBD and IBS also needs to be further explored.
This Research Topic aims at discussing the efficacy and safety of manipulation of gut microbiota through dietary interventions, probiotics, prebiotics, synbiotics, antibiotics, fecal microbiota transplantation (FMT), and other methods in the management and treatment of IBD and IBS. And we would also like to update recent advances and evidence in novel gut microbiota manipulation tools in the management and treatment of IBD and IBS. We would like to explore the exact relationship between specific gut bacteria and IBD subtypes (Ulcerative colitis and Crohn’s disease) or IBS subtypes (IBS-C, IBS-D, IBS-M), and elucidate the mechanisms underlying the role of gut microbiota or metabolites in IBD and IBS through gut immunity, gut inflammation, gut microenvironment, and gene and protein regulation.
We welcome submissions of Original Research, Reviews, and Commentaries. We would like contributors to address the following topics:
1. The efficacy and safety of manipulation of gut microbiota through dietary interventions, probiotics, prebiotics, synbiotics, antibiotics, fecal microbiota transplantation (FMT), and other methods in the management and treatment of IBD and IBS.
2. The exact relationship between specific gut bacteria and IBD subtypes (Ulcerative colitis and Crohn’s disease) or IBS subtypes (IBS-C, IBS-D, IBS-M).
3. The mechanisms underlying the role of gut microbiota or its metabolites in IBD and IBS.
